Strategy and Study: Digitalization Moves Global Health Consumption Up to 4.4 to 2030 ... 2

Strategy and Study: Digitalization Moves Global Health Consumption Up to 4.4 to 2030 …

In terms of healthcare growth, surveyed pharmaceutical executives expect large changes in consumption by 2030 compared to 2018, especially in diagnostics (+ 524%), prevention (+ 244%) and digital health (+ 205%). By contrast, the share of health care in total healthcare spending will be reduced by almost 16%. This represents a reduction of about USD 1.2 billion globally by 2030. For the German market the drop in medical care amounts to $ 28 billion, while the area of ​​prevention is $ 39 billion. digital health services will grow by $ 32 billion.

"In our research, health managers expect unsafe times for their current business model. Traditional pharmaceutical companies either need to become much more effective in maintaining their margins, or invest in growth areas such as diagnostics, prevention, and digital healthcare solutions. strategic decisions since technology companies have been pushing the market for years and working on a digital offering. The number of partnerships, acquisitions and ventures of major players such as Amazon, Alpha, Apple, Alibaba and Tencent have increased in the healthcare sector between 2014 and today In addition, these companies now have more than 6,000 health-related patents, "Dr. Thomas Solbach, Health Expert and Partner in Strategy & Germany.

Among the interviewed pharmacist managers, the vast majority are confident that change for their own industry is inevitable. 96% agree with the statement that health care will focus on informed and self-determined people in the future and focus on preventive, personalized and integrated digital services. Diseases are only partly cured because they are not developed at all or just later, due to focus on preventive measures. According to managers, the new ecosystem will be developed based on innovative organizational and business models and changed regulatory requirements. 68% of respondents expect this vision of the future to become a new standard by 2030 at the latest. 75% see it as an opportunity for their businesses, as long as the pharmaceutical industry is ready to make a change active and comprehensive. So far, however, only 25% of them have taken a holistic approach to addressing these challenges.

"Businesses that enter the healthcare market have multiple initial benefits with regard to new growth areas. With its customer focus, access and data processing and agile innovations, its business models at many players are closer to digital medicine that is rapidly developing as a pharmaceutical company Traditional players, with their advancement in medical expertise and the commercialization of medical products, have to find completely new ways to overcome decades of development and urgently need to build new digital skills to secure their market share, explains Dr. Thomas Solbach.

Researchers from the pharmaceutical company also see technology companies as change drivers, while regulators are clearly rated as brakes. Among their own organizations, respondents have a mixed picture: first, they see the creation of digital consciousness and appropriate corporate culture as the biggest internal challenge (70%), followed by the development of currently missing skills (47%) and Overcoming Structural Obstacles (35%). Outside, regulatory and legal obstacles are the main concerns (71%), as well as access to and access to basic data sets (37%) and ethical issues (22%).

The full results of the Health Future Study are available at https://www.strategyand.pwc.com/en/study/futureofhealth

methodology
The study interviewed 120 managers from leading global pharmaceutical companies from all major organizational and therapeutic areas. Two thirds of the participants came from organizations with over $ 10 billion in revenue. Research results are complemented by selective interviews with leading world physicians and scientists.